Skip main navigation

Home > Search Results

Main contents starts here

Search Results

101 - 120 of about 337

Total 337 documents found.

  •  
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2010-2012 Mid-Range Plan Transformation for a New Takeda Vision Takeda's vision is to embody global pharmaceutical leadership through innovation, growth and culture guided by an unwavering commitment to significantly improve the lives of patients. Innovation based on bold leadership in science and medicine resulting in the discovery, development and delivery of high-quality, differentiated products focused on patient needs. Sustainable growth in corporate value by leveraging core therapeutic areas, and an industry-leading pipeline and product portfolio. A culture based on good corporate citizenship that empowers employees through collaboration, inclusion, trust and timely decision making. [Takeda-ism] We, the members of the Takeda G
  • 20 CSR Activity in Italy My team and I spend our lives travelling to African remote rural hospitals. The challenges of performing surgery in these hospitals are immense and outreach patients travel for miles to reach me. Despite all this, I have carried out 1,702 consultations and 801 operations during 80 outreach trips in the last twelve months. The operations make a big difference to the lives of my patients. Most of them have suffered for a long time, often since birth. The fact that we are able to make a difference in the lives of many desperate people in our region makes me proud. Takeda continues to promote initiatives based on the Takeda-ism corporate philosophy in countries around the world The Flying Doctor Service is the airborne medical services arm of AMREF, the African Medical and Research Foundation, an international non-government health organization, founded in Kenya 1957. The AMREF Flying Doctors Outreach Program serves more than 135 rural hospitals that are visited 2-6 times per year in ord
  • 44 Total energy input Purchased electricity Heavy oil City gas Coal Water [Main energy resources] 3,703 128,469 41,352 16,824K 0 5,424K million MJ MWh kL m3 tons m3 CO2 emissions Amount of waste generated Amount of waste discharged Amount of waste for final disposal SOx NOx 226,191 16,090 9,205 74 178 180 tons tons tons tons tons tons Dust COD Total phosphorus Total nitrogen 18 119 7 53 tons tons tons tons Totals for Production and Research Sites of Takeda Pharmaceutical Company Limited Totals for Takeda Group Production and Research Sites Outside of Japan ■Osaka Plant Site Data for Takeda Pharmaceutical Company Limited Acetonitrile Dichloromethane N,N-dimethylformamide Dioxins (mg-TEQ) Toluene 1.0 0.026 0.010 0.018 0.018 0 0 0 0 0 0 0 0 0 0 1.0 0.026 0.010 0.018 0.018 0.35 0.0029 0.028 0 0.0002 67 1.3 1.0 0.30 1.8 68 1.3 1.0 0.30 1.8 Releases Transfers Air emissionSubstance Water bodies Land POTWs Waste TotalTotal PRTR Data Amount of Resources Used Environmental impacts ■Hikari Plant Total energy input Pu
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000088 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market
  • Establishing ag Global Pharmaceutical Company - Key Policies for FY2009 - Yasuchika Hasegawa President Takeda Pharmaceutical Company Limited Maintaining and expanding sales Key Policies for FY2009 in Japan, the US, Europe, and Asia Enhancing R&D structure to achieve steady launch of in-house products - Strategic shift from raw IND numbers and speed to overall project quality - 1 Establishing a structure to support global business operations and accelerate human resource development Maintaining and Expanding Sales in Japan, the US, Europe, and Asia 2 Maintaining Sales of TPNA Further growth of existing mainstay products Quickest possible penetration of new products into the market M i t i i k t h f ACTOSMaintaining market share of ACTOS family through aggressive promotion KAPIDEX: Aiming to switch from PREVACID and other brand drugs ULORIC: ($MM) 3 (E) Invigorating the market as the first new gout drug in the past 40 years Maintaining No.1 Position in Japan Further growth of existing ma
  • Establishing ag Global Pharmaceutical Company - Key Policies for FY2009 - Yasuchika Hasegawa President Takeda Pharmaceutical Company Limited Maintaining and expanding sales Key Policies for FY2009 in Japan, the US, Europe, and Asia Enhancing R&D structure to achieve steady launch of in-house products - Strategic shift from raw IND numbers and speed to overall project quality - 1 Establishing a structure to support global business operations and accelerate human resource development Maintaining and Expanding Sales in Japan, the US, Europe, and Asia 2 Maintaining Sales of TPNA Further growth of existing mainstay products Quickest possible penetration of new products into the market M i t i i k t h f ACTOSMaintaining market share of ACTOS family through aggressive promotion KAPIDEX: Aiming to switch from PREVACID and other brand drugs ULORIC: ($MM) 3 (E) Invigorating the market as the first new gout drug in the past 40 years Maintaining No.1 Position in Japan Further growth of existing ma
  • On the intranet website, Philan-net Takeda (PINT), information on regional volunteer activities is transmitted for employees. "Climbing Mt. Tenno for cleaning," a voluntary project by PINT Osaka is one such example, featuring contributions to society through the activity of cleaning a mountain climbing route, using handmade bamboo tongs to grab garbage, in a step-by-step fashion. PINT also provides a variety of information on Takeda's social action programs and the introduction of NPOs, aiming to play a role as a medium to bridge social needs and the employees' aspirations toward society. The area directly related to the Mission: "we strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products" The area concerning "the aim to live an affluent life with body and mind in good health," as well as "eliminating any obstacles to such a goal" based on the Mission Contributions toward developing a bright and dream-inspiring future The projects to be inherited an
  • 30 Takeda will promote our efforts toward the establishment of the R&D pipeline, contributing to accomplish our goal: "sales of consolidated ethical products (excluding stocks) of 2 trillion in fiscal 2015," as targeted in the "2006-2010 Medium-Term Plan," by accelerating the challenge toward World Best Practice under the global research & development network. As for domestic operations, we plan to open a "new research center" in Fujisawa City, Kanagawa targeting to commence operation scheduled for fiscal 2010 and promoting toward the unification of our research bases. The Establishment and Enhancement of a Global R&D Infrastructure That Accelerates the "Enhancing Strategies for the Area of Oncology Diseases" Takeda positions lifestyle-related diseases, oncology and urological diseases (including gynecological disorders), central nervous system diseases (including bone and joint diseases) and gastroenterological diseases as its core therapeutic areas and promotes efforts based on the Tikarakobu Research Stra
  • 72 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2007 2006 2007 Current assets: Cash and cash equivalents 1,647,694 1,626,235 $13,963,508 Marketable securities (Note 5) 92,342 243,285 782,559 Short-term investments 59,900 507,627 Notes and accounts receivable Trade notes 20,695 21,137 175,381 Trade accounts 232,639 207,887 1,971,517 Due from affiliates 8,641 7,656 73,229 Allowance for doubtful receivables (535) (309) (4,534) Total 261,440 236,371 2,215,593 Inventories (Note 6) 105,307 98,258 892,432 Deferred tax assets (Note 12) 139,223 135,019 1,179,856 Other current assets 51,807 32,802 439,044 Total current assets 2,357,713 2,371,970 19,980,619 Property, plant and equipment (Note 7): Land 62,271 44,853 527,720 Buildings and structures 256,546 247,106 2,174,119 Machinery and equipment 233,693 218,161 1,980,449 Tools and fixtures 63,191 61,888 535,517 Construction in progress 4,987 20,260 42,263 Total 620,688 592,268 5,260,068 Accumulated depreciation (382,242) (376,598) (3,239,339) Net property
  • Takeda has established the Human Resources Vision: "we develop a high-performance, results-oriented culture within our organization with motivated employees who take pride in and find a sense of accomplishment from their work." as a basic human resource principle. Takeda has previously implemented various reforms in terms of personnel affairs, and these initiatives have been compiled into the "Human Resources Philosopies" in order to realize the "Human Resources Vision." These philosopies describe the basic principles and concept regarding the personnel system and its operation, such as recruitment, assignment, development, assessment and compensation, and the Company implements human resources programs based on the philosophies. Based on the 2006 - 2010 Medium-Term Management Plan, we have been proactively and intensively working to establish effective and efficient human resource management from global perspectives for "growth toward a world-class pharmaceutical company with Japanese Origin." The Strategic
  • Throughout a history of more than 220 years "creating medicine," Takeda has developed a strong sense of mission and high ethical standards. During this long history, Takeda sees social action programs as an "investment in society," having been addressing various efforts. Based on increasing recognition of "corporate social responsibilities" associated with progress of globalization of society, in 2005, Takeda systematically organized a number of previous activities and placed them into statutory form, such as "Basic Policy on Social Contribution." This policy is shared among the global Takeda group and we have been implementing activities at a global level, centering on four priority areas. Since corporate activities would never be realized without the sustained progress of society, social action programs can be positioned as one of the important company activities. Actually, this concept is nothing new to Japanese, given the long-held philosophy of "Sanpo-yoshi (Where all three parties are happy)." This ter
  • Consolidated Financial Statements for the Interim Period of Fiscal 2006 November 6, 2006 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Board of Directors meeting: November 6, 2006 Representative: Yasuchika Hasegawa, President Use of U.S. accounting standards: No Contact: Toyoji Yoshida, Director Telephone: +81-6-6204-2060, +81-3-3278-2039 1. Results for the Interim Period of Fiscal 2006 (April 1, 2006-September 30, 2006) (1) Consolidated Operating Results (All amounts are rounded to the nearest million yen.) Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Interim period of fiscal 2006
  • 68 Takeda Annual Report 2006 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2006 2005 2006 Current assets: Cash and cash equivalents 1,626,235 1,264,324 $13,899,444 Marketable securities (Note 3) 243,285 257,796 2,079,359 Notes and accounts receivable Trade notes 21,137 19,509 180,658 Trade accounts 207,887 197,141 1,776,812 Due from affiliates 7,656 8,764 65,436 Allowance for doubtful receivables (309) (271) (2,641) Total 236,371 225,143 2,020,265 Inventories (Note 4) 98,258 94,565 839,812 Deferred tax assets (Note 12) 135,019 93,857 1,154,009 Other current assets 32,802 34,230 280,359 Total current assets 2,371,970 1,969,915 20,273,248 Property, plant and equipment (Notes 5 and 6): Land 44,853 44,500 383,359 Buildings and structures 247,106 257,419 2,112,017 Machinery and equipment 218,161 241,495 1,864,624 Tools and fixtures 61,888 60,162 528,957 Construction in progress 20,260 20,927 173,162 Total 592,268 624,503 5,062,119 Accumulated depreciation (376,598) (404,370) (3,218,786) Net property,
  • Takeda is actively working to establish a strong corporate culture that encourages all employees to work with energy and enthusiasm. EmployeeRelationship with Takeda Annual Report 200652 SURVEY ON CORPORATE CULTURE AND EMPLOYEE SATISFACTION IN JAPAN Takeda implemented an employee survey on corporate culture and employee satisfaction in June 2005. With 92.4 percent of employees responding, the survey aimed to identify needs that foster a corporate culture where all employees are encouraged to work with energy and enthusiasm. The survey was also an opportunity to understand what issues need to be addressed in order to improve strategies in the corporate culture and help Takeda employees realize the corporate business strategy with a sense of unity. The survey questions were prepared based on our Corporate Values under the Corporate Philosophy, and the results were analyzed by classifying the Corporate Values into 18 indicators, breaking them down into concrete actions. Based on the survey results, we were able
  • 1 1 Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited President Yasuchika Hasegawa May 11, 2007 Management PolicyManagement Policy 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006-2010 Medium-Term Management Plan Enhancement of R&D pipeline Comprehensive improvement of strengths as a Japanese company Establishment and in-depth implementation of strategies from a long-term perspective High productivity and efficiency Growth toward a World-class Pharmaceutical Company with Japanese Origin, based on Takeda-ism Growth toward a World-class Pharmaceutical Company with Japanese Origin, based on Takeda-ism Securing human resources Improvement of the presence 2 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006-2010 Medium-Term Management Plan Operational targets FY06 (Actual) FY07 (Estimate) Net sales: mid-single digit growth 1,305.2 billion yen (+7.7%) 1,390.0 billion yen (+6.5%) R&D expenses: late-single digit increase 193.3
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000055 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2039 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html [Takeda-ism] We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavors to fulfill our mission to "strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products." 2
  • 38 CONSOLIDATED BALANCE SHEETS Takeda Pharmaceutical Company Limited and Subsidiaries Years ended March 31, 2005 and 2004 Thousands of Millions of yen U.S. dollars (Note 1) 2005 2004 2005 ASSETS Current assets: Cash and cash equivalents 1,264,324 1,076,084 $11,816,112 Time deposits 5,000 Marketable securities (Note 3) 257,796 241,670 2,409,308 Notes and accounts receivable Trade notes 19,509 22,087 182,327 Trade accounts 197,141 179,495 1,842,439 Due from affiliates 8,764 8,208 81,907 Allowance for doubtful receivables (271) (641) (2,533) Total 225,143 209,149 2,104,140 Inventories (Note 4) 94,565 92,931 883,785 Deferred income taxes (Note 13) 93,857 81,367 877,168 Other current assets 34,230 23,946 319,908 Total current assets 1,969,915 1,730,147 18,410,421 Property, plant and equipment (Notes 5, 6 and 7): Land 44,500 54,256 415,888 Buildings and structures 257,419 255,580 2,405,785 Machinery and equipment 301,657 279,671 2,819,224 Construction in progress 20,927 26,361 195,579 Total 624,503 615,868 5,836,4
  • To Our Shareholders: 02 A NEW START AS THE TAKEDA PHARMACEUTICAL COMPANY In fiscal 2003 we laid the groundwork for an aggressive effort to become an R&D-driven, world-class pharmaceutical company. To support this initiative, we established a global management system for our marketing, production, development, research, alliance, and intellectual property management functions, along with other strategic changes. One of those moves was the creation of a new senior management structure consisting of a chief executive officer (CEO) and a chief operating officer (COO) in June 2003 to accelerate decision-making, enhance operational agility, and increase overall transparency. Under this new structure, the chairman of the board acts as the CEO and is ultimately responsible for the performance of Takeda, including oversight of senior executives and strategic decisionmaking, while the president serves as the COO and is responsible for the Company's performance. With respect to internal control, the Auditing Department
  • 34 Consolidated Balance Sheets: Takeda Pharmaceutical Company Limited (Formerly Takeda Chemical Industries, Ltd.) and Subsidiaries Years ended March 31, 2004 and 2003 Thousands of Millions of yen U.S. dollars (Note 1) 2004 2003 2004 ASSETS Current assets: Cash and cash equivalents 1,076,084 1,022,958 $10,151,738 Time deposits 5,000 25,000 47,170 Marketable securities (Note 3) 241,670 118,427 2,279,908 Notes and accounts receivable Trade notes 22,087 23,496 208,372 Trade accounts 179,495 168,923 1,693,352 Due from affiliates 8,208 10,224 77,425 Allowance for doubtful receivables (641) (704) (6,046) Total 209,149 201,939 1,973,103 Inventories (Note 4) 92,931 89,485 876,705 Deferred income taxes (Note 12) 81,367 62,749 767,611 Other current assets 23,946 21,640 225,907 Total current assets 1,730,147 1,542,198 16,322,142 Property, plant and equipment (Notes 5 and 6): Land 54,256 55,036 511,848 Buildings and structures 255,580 240,941 2,411,131 Machinery and equipment 279,671 296,787 2,638,401 Construction in pro

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top